The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I clinical trial of namitecan (ST1968): Results with D1-3 q3wks schedule.
A. Fasolo
No relevant relationships to disclose
G. Del Conte
No relevant relationships to disclose
R. G. Calderone
No relevant relationships to disclose
E. Gallerani
No relevant relationships to disclose
N. Hagner
No relevant relationships to disclose
P. Barbieri
Employment or Leadership Position - Sigma-Tau
L. Luraghi
Employment or Leadership Position - Sigma-Tau
S. Pace
Employment or Leadership Position - Sigma-Tau
F. Capocasa
Employment or Leadership Position - Sigma-Tau
N. Coceani
Employment or Leadership Position - SENDO Tech
E. Maccioni
Employment or Leadership Position - SENDO Tech
D. Hess
No relevant relationships to disclose
C. Sessa
Consultant or Advisory Role - Sigma-Tau
Research Funding - Sigma-Tau
L. Gianni
Consultant or Advisory Role - Biogen Idec; Boehringer Ingelheim; Eisai; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi ; Takeda; Wyeth